Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis

Published:2017-05 Issue:11 Volume:13 Page:1021-1034
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Li Lun¹,Han Dongdong²,Wang Xiaowei³,Wang Quan⁴,Tian Jinhui⁵,Yao Jia¹,Yuan Liqin¹,Qian Ke¹,Zou Qiongyan¹,Yi Wenjun¹,Zhou Enxiang¹,Yang Kehu⁵

Affiliation:

1. Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China

2. Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, China

3. Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, China

4. Department of Gastrointestinal Surgery, Xijing Hospital of Digestive Diseases, Xijing Hospital, Four Military Medical University, Xi'an, Shaanxi, China

5. Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China

Abstract

Aim: To assess the prognostic values of Ki-67 in neoadjuvant setting for breast cancer patients. Methods: PubMed and EMBASE were searched. Revman software was used to conduct random-effect model meta-analysis. Results: 49 studies (14,076 patients) were included. High Ki-67 before and after neoadjuvant chemotherapy were associated with worse overall survival (OS; before: hazard ratio [HR]: 2.29; 95% CI: 1.42–3.69; after: HR: 2.24; 95% CI: 1.82–2.75) and disease-free survival (DFS; before: HR: 1.54; 95% CI: 1.23–1.95; after: HR: 2.08; 95% CI: 1.83–2.37). Low/no reduction or increase might be associated with worse DFS (HR: 2.13; 95% CI: 1.51–3.02) and OS. Conclusion: Ki-67 before and after neoadjuvant chemotherapy, as well as the change could predict the prognosis for breast cancer patients.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2016-0428

Reference54 articles.

1. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer

2. Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer

3. Prognostic significance of Ki67 index after neoadjuvant chemotherapy in breast cancer

4. Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer;Current Medical Science;2024-02-02

2. Machine Learning with Multiparametric MRI-based Radiomics Models for Preoperative Prediction of Ki-67 Status in Luminal Breast Cancer;2023-11-14

3. Heterogeneous circulating tumor cells correlate with responses to neoadjuvant chemotherapy and prognosis in patients with locally advanced breast cancer;Breast Cancer Research and Treatment;2023-06-13

4. Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer;Cancers;2023-06-06

5. Prognostic analysis of three forms of Ki‐67 in patients with breast cancer with non‐pathological complete response before and after neoadjuvant systemic treatment;Cancer Medicine;2023-02-16